Antalis E, Oikonomopoulou Z, Kottaridi C, et al. Mixed viral infections of the respiratory tract; an epidemiological study during consecutive winter seasons. J Med Virol. 2018;90: 663--670. 10.1002/jmv.25006 29244214

This study was presented in part in poster form: Abstract No 545, during the 2015 IDWEEK conference, October 7‐11, San Diego Convention Center, San Diego, CA.

1. INTRODUCTION {#jmv25006-sec-0002}
===============

Seasonal patterns of respiratory viruses circulation and detection in human infections are hard to explain. It has been suggested that based on seasonal variation and the clinical syndrome seen, one can predict what type of virus is implicated.[1](#jmv25006-bib-0001){ref-type="ref"}, [2](#jmv25006-bib-0002){ref-type="ref"} Limited data exist, with regards to the clinical importance of mixed respiratory viral infections during the winter season. *Influenza* and *respiratory syncytial virus* (*RSV*) are well known to circulate in winter.[1](#jmv25006-bib-0001){ref-type="ref"}, [3](#jmv25006-bib-0003){ref-type="ref"} The extent of overlap, the possibility of dual infections and associations of mixed respiratory viral infections with clinical and epidemiological data needs further elucidation. Point of Care testing and newer available molecular techniques have improved our ability to detect diverse viruses causing respiratory infections.[4](#jmv25006-bib-0004){ref-type="ref"} In a recent study evaluating two different multiplex kits 14.2% of samples tested, harbored viral co‐infections.[4](#jmv25006-bib-0004){ref-type="ref"} Limited studies have evaluated the presence of mixed viral infections at the clinical setting for adult populations. Significant rates of mixed infections have been reported in several studies mainly involving pediatric populations[5](#jmv25006-bib-0005){ref-type="ref"}, [6](#jmv25006-bib-0006){ref-type="ref"}, [7](#jmv25006-bib-0007){ref-type="ref"}, [8](#jmv25006-bib-0008){ref-type="ref"}, [9](#jmv25006-bib-0009){ref-type="ref"}, [10](#jmv25006-bib-0010){ref-type="ref"}, [11](#jmv25006-bib-0011){ref-type="ref"}, [12](#jmv25006-bib-0012){ref-type="ref"}, [13](#jmv25006-bib-0013){ref-type="ref"}, [14](#jmv25006-bib-0014){ref-type="ref"} while very little data exist regarding adult patients.[15](#jmv25006-bib-0015){ref-type="ref"}, [16](#jmv25006-bib-0016){ref-type="ref"}, [17](#jmv25006-bib-0017){ref-type="ref"}, [18](#jmv25006-bib-0018){ref-type="ref"} The clinical significance of mixed viral infections is a matter of debate with some data supporting a role for increased illness severity and adverse outcomes including hospitalizations[5](#jmv25006-bib-0005){ref-type="ref"}, [15](#jmv25006-bib-0015){ref-type="ref"} and some not.[9](#jmv25006-bib-0009){ref-type="ref"}, [10](#jmv25006-bib-0010){ref-type="ref"}, [16](#jmv25006-bib-0016){ref-type="ref"} Further, most of the studies are biased towards studying hospitalized subjects[9](#jmv25006-bib-0009){ref-type="ref"}, [10](#jmv25006-bib-0010){ref-type="ref"}, [19](#jmv25006-bib-0019){ref-type="ref"}, [20](#jmv25006-bib-0020){ref-type="ref"} and very little data exist regarding outpatients.[16](#jmv25006-bib-0016){ref-type="ref"}, [17](#jmv25006-bib-0017){ref-type="ref"}, [18](#jmv25006-bib-0018){ref-type="ref"}

The current study aimed to describe the molecular epidemiology of mixed respiratory viral infections in both adults and children within the context of acute respiratory illness. The study was part of a molecular epidemiology study of respiratory viruses detection in patients presenting with acute respiratory symptoms during consecutive winter seasons, in a tertiary care hospital Emergency Room (ER), in a large metropolitan area.

The study\'s main aim was to identify the prevalence of such infections within the population sampled. An additional aim was to correlate the detection of mixed respiratory viral infection with baseline clinical and epidemiological data, including the decision to hospitalize due to severe illness.

2. MATERIALS AND METHODS {#jmv25006-sec-0003}
========================

Patients with symptoms of respiratory tract infection (RTI) (i.e., fever and/or cough and/or other symptoms suggestive of a respiratory infection e.g., nasal congestion, rhinorrhea, sore throat) presenting to the Emergency Room (ER) of the tertiary care university hospital Attikon (Athens, Greece) during the winter season (i.e., November to March each season) of 2009‐11 (two seasons) and 2013‐2015 (two seasons) were evaluated during the study. Data were not collected for the seasons 2011‐12 and 2012‐13. After informed consent was provided, a respiratory sample was collected from each patient through a standardized technique (sputum sample obtained after a 5 s observed mouth gargle with normal saline involving the entire oropharyngeal area) into ThinPrep CytoLyt^®^ solution (Cytyc Corporation, Malborough, MA) and was immediately submitted to the collaborating research laboratory. Basic clinical and epidemiological characteristics for each patient were collected through a structured case report form. All procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation (Scientific council of the University Hospital Attikon) and with the Helsinki Declaration of 1975, as revised in 2008.

Viral RNA was extracted using 400 µL of ThinPrep CytoLyt solution using the MagMAX™ Viral RNA Isolation Kit and eluted in 50 µL elution buffer. The CLART^®^ *PneumoVir* kit was used (GENOMICA, Madrid, Spain) that detects the presence of the 17 most frequent types of human viruses causing respiratory infections. The molecular procedure was followed according to the manufacturer\'s instructions. Virus amplification was performed via two RT (reverse transcriptase) multiplex PCR reactions and the detection/visualization was performed based on low‐density micro‐arrays. Negative controls were included in each experiment.

Study prevalence rates together with 95% Confidence Intervals were calculated for each virus (as denominator, the entire population sampled was used). Data on influenza detection were compared with National influenza surveillance data (for the respective years) available through the Hellenic Center for Disease Control and Prevention. Correlation between type of virus, mixed virus detection and age status (children if age \<18 years old) was performed using chi‐square test. Univariate and multivariate analysis was used to evaluate associations between specific virus detection, mixed virus detection, clinical characteristics, for example, fever and the outcome of hospitalization. SPSS version 22.0 for Windows software (SPSS, Inc., Chicago, IL) was used for data analysis. All tests were two tailed.

3. RESULTS {#jmv25006-sec-0004}
==========

Overall 604 consecutive patients with RTI were evaluated during the study period. Demographics of the study population according to age, gender, comorbidities, and type of virus detected are shown in Tables [1](#jmv25006-tbl-0001){ref-type="table"} and [2](#jmv25006-tbl-0002){ref-type="table"}. The median age for the entire group was 42.4 years (IQR 25‐62 years) and 296 (49%) were female. The vast majority of the population were adults (*n* = 498, 82.5%) whereas 106 (17.5%) children were examined. Of 402 patients with available data 206 (51.2%) had comorbidities, like Chronic Obstructive Pulmonary Disease (COPD) (*n* = 125/402, 31.1%) and cardiovascular disease (*n* = 105/402, 26.1%, Table [1](#jmv25006-tbl-0001){ref-type="table"}).

###### 

Demographics of the study population

  Variables, *n* (%)                        Any virus, *n* (%) *N* = 332/604 (55)                      Influenza, *n* (%) *n *= 194/604 (32.1)                    *RSV*, *n* (%) *n *= 142/604 (23.5)                       Mixed virus, (%) *n *= 68/604 (11.3)   Mixed *RSV*/Flu, *n* (%) *n *= 45/604 (7.5)
  ----------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------- -------------------------------------- -------------------------------------------------------
  Female gender, *n* (%)                    169/332 (50.9)                                             98/194 (50.5)                                              70/142 (49.3)                                             33/68 (48.5%)                          20/45 (44.4)
  Age 0‐4 yrs, *n *= 37 (6.1)               31/332 (9.3)                                               5/194 (2.6)                                                27/142 (19)                                               10/68 (14.7)                           4/45 (8.9)
  Age 5‐17 yrs, *n* = 69 (11.4)             53/332 (16)                                                27/194 (13.9)                                              34/142 (23.9)                                             15/68 (22.1)                           11/45 (24.4)
  Age 18‐40 yrs, *n *= 208 (34.4)           101/332 (30.4)                                             65/194 (33.5)                                              41/142 (28.9)                                             23/68 (33.8)                           16/45 (35.6)
  Age 41‐65 yrs, *n *= 161 (26.7)           84/332 (25.3)                                              56/194 (28.9)                                              27/142 (19)                                               14/68 (20.6)                           11/45 (24.4)
  Age \>65 yrs, *n *= 129 (21.4)            63/332 (19)                                                41/194 (21.1)                                              13/142 (9.2)                                              6/68 (8.8)                             3/45 (6.7)
  Hospitalization, *n = *165 (27.3)         92/332 (27.7)                                              62/194 (32)                                                22/142 (15.5)[^\*^](#jmv25006-note-0003){ref-type="fn"}   9/68 (13.2)                            6/45 (13.3)[^\*^](#jmv25006-note-0003){ref-type="fn"}
  Any comorbidities, *n *= 206/402 (51.2)   180/402 (44.8)                                             127/402 (31.6)[^\*^](#jmv25006-note-0003){ref-type="fn"}   22/402 (5.5)                                              10/402 (2.5)                           3/402 (0.7)
  Age ≩18 yrs                               165/180 (91.7)[^\*^](#jmv25006-note-0003){ref-type="fn"}   114/127 (89.8)[^\*^](#jmv25006-note-0003){ref-type="fn"}   22/22 (100)                                               10/10 (100)                            3/3 (100)
  COPD, *n *= 125 (31.1)                    67/180 (37.2)[^\*^](#jmv25006-note-0003){ref-type="fn"}    50/127 (39.3)[^\*^](#jmv25006-note-0003){ref-type="fn"}    8/22 (36.4)                                               5/10 (50)                              2/3 (66.7)
  CVD, *n* = 105 (26.1)                     58/180 (32.2)[^\*^](#jmv25006-note-0003){ref-type="fn"}    43/127 (33.9)[^\*^](#jmv25006-note-0003){ref-type="fn"}    5/22 (22.7)                                               4/10 (40)                              1/3 (33.3)
  Diabetes, *n *= 62 (15.4)                 30/180 (16.7)                                              23/127 (18.1)                                              3/22 (13.6)                                               2/10 (20)                              1/3 (33.3)
  Malignancy, *n *= 21 (5.2)                10/180 (5.6)                                               6/127 (4.7)                                                0/22 (0)                                                  0/10 (0)                               0/3 (0)
  ESRD, *n* = 7 (1.7)                       3/180 (1.7)                                                2/127 (1.6)                                                0/22 (0)                                                  0/10 (0)                               0/3 (0)
  Allergy, *n* = 44 (10.9)                  17/180 (9.4)                                               13/127 (10.2)                                              2/22 (9.1)                                                1/10 (10)                              0/3 (0)
  Smoking, *n* = 174 (43.3)                 69/180 (38.3)                                              46/127 (36.2)                                              9/22 (40.9)                                               6/10 (60)                              3/3 (100)
  Influenza vaccine, *n* = 84 (20.9)        41/180 (22.8)                                              27/127 (21.3)                                              6/22 (27.3)                                               3/10 (30)                              1/3 (33.3)
  Hospitalization, *n* = 142 (35.3)         76/180 (42.2)[^\*^](#jmv25006-note-0003){ref-type="fn"}    56/127 (44.1)                                              10/22 (45.5)[^\*^](#jmv25006-note-0003){ref-type="fn"}    5/10 (50)                              3/3 (100)

Patients with Influenza‐like illness but no virology data were excluded. For comorbidities data are shown only for patients with available data (*n* = 402). Statistical significance for comparisons between groups with positive results and the rest of the group are flagged with an asterisk.

COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; ESRD, end stage renal disease.

Statistically significant associations (*P* \< 0.05) are flagged.
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###### 

Prevalence of identified viruses in the total population and in adults and children for patients with available virology data

  Virus                     Total population, *n* = 604   Adults, *n*, % (95%CI) *n *= 498                                        Children, *n*, % (95%CI) *n *= 106
  ------------------------- ----------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------
  Any virus (+)             332/604, 55% (50.9‐59%)       248/498, 49.8% (45.3‐54.3%)[^\*^](#jmv25006-note-0005){ref-type="fn"}   84/106, 79.2% (70.1‐86.3%)[^\*^](#jmv25006-note-0005){ref-type="fn"}
  Influenza, total          194/604, 32.1% (28.4‐36%)     162/498, 32.5% (28.5‐36.9%)                                             32/106, 30.2% (21.9‐40%)
  Influenza A, *n* (%)      120/604, 19.9% (16.8‐23.3%)   101/498, 20.3% (16.9‐24.1%)                                             19/106, 17.9% (11.4‐26.8%)
  Influenza B               75/604, 12.4% (9.9‐15.4%)     62/498, 12.4% (9.7‐15.7%)                                               13/106, 12.3% (7‐20.4%)
  RSV, total                142/604, 23.5% (20.2‐27.1%)   81/498, 16.3% (13.2‐19.9%)[^\*^](#jmv25006-note-0005){ref-type="fn"}    61/106, 57.5% (47.6‐67%)[^\*^](#jmv25006-note-0005){ref-type="fn"}
  RSV A                     78/604, 12.9% (10.4‐15.9%)    40/498, 8% (5.9‐10.9%)[^\*^](#jmv25006-note-0005){ref-type="fn"}        38/106, 35.8% (26.9‐45.8%)[^\*^](#jmv25006-note-0005){ref-type="fn"}
  RSV B                     110/604, 18.2% (15.3‐21.6%)   59/498, 11.8% (9.2‐15.1%)[^\*^](#jmv25006-note-0005){ref-type="fn"}     51/106, 48.1% (38.4‐58%)[^\*^](#jmv25006-note-0005){ref-type="fn"}
  Parainfluenza viruses     18/604, 3% (1.8‐4.8%)         17/498, 3.4% (2.1‐5.5%)                                                 1/106, 0.9% (0.05‐5.9%)
  Rhinovirus                16/604, 2.6% (1.6‐4.4%)       12/498, 2.4% (1.3‐4.3%)                                                 4/106, 3.8% (1.2‐9.9%)
  Human metapneumovirus     13/604, 2.2% (1.2‐3.8%)       7/498, 1.4% (0.6‐3%)[^\*^](#jmv25006-note-0005){ref-type="fn"}          6/106, 5.7% (2.3‐12.4%)[^\*^](#jmv25006-note-0005){ref-type="fn"}
  Adenovirus                6/604, 1% (0.4‐2.3%)          3/498, 0.6% (0.2‐1.9%)                                                  3/106, 2.8% (0.7‐8.7%)
  Bocavirus                 2/604, 0.3% (0.1‐1.3%)        0/498, 0% (0‐%)[^\*^](#jmv25006-note-0005){ref-type="fn"}               2/106, 1.9% (0.3‐7.3%)[^\*^](#jmv25006-note-0005){ref-type="fn"}
  Coronavirus               1/604, 0.2% (0.0‐1.1%)        1/498, 0.2% (0.01‐1.3%)                                                 0/106, 0% (0‐4.3%)
  Echovirus                 1/604, 0.2% (0.01‐1.1%)       1/498, 0.2% (0.01‐1.3%)                                                 0/106, 0% (0‐4.3%)
  Mixed RSV and influenza   45/604, 7.5% (5.5‐9.9%)       30/498, 6% (4.2‐8.6)[^\*^](#jmv25006-note-0005){ref-type="fn"}          15/106, 14.25 (8.4‐22.6%)[^\*^](#jmv25006-note-0005){ref-type="fn"}
  Mixed viral infections    68/604, 11.3% (8.9‐14.1%)     43/498, 8.6% (6.4‐11.5%)[^\*^](#jmv25006-note-0005){ref-type="fn"}      25/106, 23.6% (16.1‐33%)[^\*^](#jmv25006-note-0005){ref-type="fn"}

*N* over total population in each category is depicted, followed by prevalence rate and 95%CI in brackets.

Denotes *P* \< 0.05.
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In 332 out of 604 (55%, 95%CI: 50.9%‐59%) patients a respiratory virus was identified (Tables [1](#jmv25006-tbl-0001){ref-type="table"} and [2](#jmv25006-tbl-0002){ref-type="table"}). Rates of specific respiratory virus detection, as well as, mixed virus infections according to adult or child status are shown in Tables [1](#jmv25006-tbl-0001){ref-type="table"} and [2](#jmv25006-tbl-0002){ref-type="table"}. The identification of viral infection was more common in children in all seasons (OR 3.8, 95% CI 2.3‐6.4, *P *\< 0.001, Table [2](#jmv25006-tbl-0002){ref-type="table"}). Confirmed influenza had a prevalence of 32.1% (95%CI: 28.4‐36%) while *Respiratory Syncytial Virus* (*RSV*) was detected in 23.5% (95%CI: 20.2‐27.1%) of all patients (Table [2](#jmv25006-tbl-0002){ref-type="table"}). Virus positivity was more common in patients with comorbidities (OR 1.5, 95%CI 1.04‐2.3, *P *= 0.03). This association was driven by *influenza* virus positivity (OR 1.7, 95%CI 1.1‐2., *P* ≤ 0.01) and was not found for other viruses. Any virus positivity was more common in patients with COPD (OR 1.7, 95%CI 1.1‐2.6, *P* ≤ 0.01) or cardiovascular disease (OR 1.8, 95%CI 1.1‐2.8, *P* ≤ 0.01). In sub‐analyses, this was shown again to be specific for influenza detection (OR 1.7, 95%CI 1.1‐2.7, *P* = 0.02 and OR 1.8, 95%CI 1.1‐2.8, *P* = 0.02, respectively).

Table [3](#jmv25006-tbl-0003){ref-type="table"} depicts variability of study results according to study year and available data through the National sentinel Influenza‐like illness (ILI) and influenza surveillance network. Influenza strains identified during our study for the most part correlated with those circulating at the National level during the years of the study. During the 2009‐10 and 2010‐11seasons the predominant virus identified during the study was *RSV* (Table [2](#jmv25006-tbl-0002){ref-type="table"}). In both instances study samples were collected during periods of high influenza activity according to national data (Table [3](#jmv25006-tbl-0003){ref-type="table"}).

###### 

Variability in viral detection per season studied and comparison to national data regarding influenza surveillance available from the Hellenic Center for Disease Control and Prevention

                                               2009‐10         2010‐11          2013‐14        2014‐15                                                                                             
  -------------------------------------------- --------------- ---------------- -------------- ----------------- ---------- ----------------- ---------- ----------------- ------- ------- ------- -------
  Influenza season, week/year, national data   48/09           04/10            15/10          52/10             05/11      13/11             52/13      09/14             16/14   51/14   09/15   20/15
  Study period, week/year                      48/09‐04/10     03/11‐11/11      47/13‐20/14    43/14‐13/15                                                                                         
  National (N)/Study (S) data                  National        Study *n *= 94   National       Study *n *= 106   National   Study *n *= 133   National   Study *n *= 271                           
  Influenza (+) in ILI                         56.4%           43.6%            55.2%          23.6%             30.7%      16.5%             39.9%      39.1%                                     
  Influenza A                                  100%            100%             95.4%          92%               95.8%      95.5%             41%        32.1%                                     
  Influenza A (H1N1) pdm09 in total A          99.8%           100%             98.9%          95.7              79.4%      100%              12.5%      14.3%                                     
  Influenza A (H3N2) in total A                0.2%            0%               1.1%           4.3%              20.6%      0%                86.7%      85.7%                                     
  Influenza B                                  0%              0%               4.6%           0.9%              4.2%       0.8%              59%        26.9%                                     
  RSV (+) study data                           45/94 (47.9%)   75/106 (70.8%)   12/133 (9%)    10/271 (3.7%)                                                                                       
  Mixed virus infection                        27/94 (28.7%)   31/106 (29.2%)   1/133 (0.8%)   9/271 (3.3%)                                                                                        
  Mixed *Influenza* and *RSV*                  23/94 (24.5%)   19/106 (17.9%)   0/133 (0%)     3/271 (1.1%)                                                                                        

*RSV*, respiratory syncytial virus.
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*RSV* positivity ranged from 3.7% during the 2014‐15 season to 70.8% during the 2010‐11 season (*P *\< 0.01) (Table [3](#jmv25006-tbl-0003){ref-type="table"}). Variability of virus detection per collected samples, per week of study during the 2010‐11 season, is shown in Figure [1](#jmv25006-fig-0001){ref-type="fig"}. Eighty‐one out of 498 (16.3%) adults had an *RSV* infection compared to 61 out of 106 (57.5%) children (OR 7, 95%CI 4.4‐11, *P* \< 0.001, Tables [1](#jmv25006-tbl-0001){ref-type="table"} and [2](#jmv25006-tbl-0002){ref-type="table"}). *RSV* positivity according to comorbidity status is shown in Table [1](#jmv25006-tbl-0001){ref-type="table"}.

![Variability of virus detection per collected samples (in %, one equals 100%) during the 2010‐11 season per week of study](JMV-90-663-g001){#jmv25006-fig-0001}

Mixed viral infections were diagnosed in 68/332 (20.5%) patients where any virus was detected (Table [4](#jmv25006-tbl-0004){ref-type="table"}); 45 out of the 68 (66.2%) represented mixed influenza and *RSV* infections. Mixed viral infections were more common in children than adults (OR 3.7; 95%CI 1.9‐5.6, *P *\< 0.01). In logistic regression analyses, mixed infections were associated with younger age (mean age 30.4 yrs vs. 41.8, beta −0.02, OR: 0.98, 95%CI 0.97‐0.99, *P* ≤ 0.001) and increased rates of fever (63/68 \[92.6%\] pts vs. 217/264 \[82.2%\] pts, OR: 2.7; 95%CI 1.04--7.2, *P* \< 0.05). Although, no statistical association was detected mixed viral infections were more frequent than single infections in patients with comorbidities (7 out of 206 \[3.4%\] patients vs. 3/196 \[1.5%\]), patients with COPD (50% vs. 36.5%), cardiovascular disease (40% vs. 31.8), diabetes mellitus (20% vs. 16.5%); the association approached statistical significance in smokers (60% vs. 37.1%, *P* = 0.19). Patients with mixed infections were less frequently hospitalized compared to patients with single infections (13.2% vs. 31.4%, *P* = 0.002).

###### 

Epidemiological characteristics of patients with mixed viral infections versus those with single viral infection

                                                               Single virus, *n* = 264   Mixed virus, *n* = 68                                    *P*
  ------------------------------------------------------------ ------------------------- -------------------------------------------------------- --------
  Age, mean ± SD in yrs                                        41.8 ± 25.6               30.4 ± 23                                                ≤0.001
  Child, *n* (%), *n *= 84/332 (25.3)                          59/264 (22.3)             25/68 (36.8)                                             0.01
  COPD, *n* (%), *n *= 67/180                                  62/170 (36.5)             5/10 (50)                                                0.5
  Cardiovascular disease, *n* (%), *n *= 58/180 (32.2)         54/170 (31.8)             4/10 (40)                                                0.7
  Diabetes, *n* (%), *n *= 30/180 (16.7)                       28/170 (16.5)             2/10 (20)                                                0.7
  Neoplastic disease, *n* (%), *n *= 10/180 (5.6)              10/170 (5.9)              0/10 (0)                                                 1
  History of allergic condition, *n* (%), *n* = 17/180 (9.4)   16/170 (9.4)              1/10 (10)                                                1
  Chronic renal diseases, *n* (%), *n *= 3/170 (1.7)           3/170 (1.8)               0 (0)                                                    1
  Tobacco use, *n* (%), *n *= 69/180 (38.3)                    63/170 (37.1)             6/10 (60)                                                0.19
  Influenza vaccination, *n* (%), *n *= 41/180 (22.8)          38/170 (22.4)             3/10 (30)                                                0.7
  Fever, *n* (%), *n *= 280/332 (84.3)                         217/264 (82.2)            63/68 (92.6)[^\*^](#jmv25006-note-0009){ref-type="fn"}   0.039
  Hospitalization, *n* (%), *n *= 92/332 (27.7)                83/264 (31.4)             9/68 (13.2)[^\*^](#jmv25006-note-0009){ref-type="fn"}    0.002

Data for comorbidities were available only for 180 people of the study population. *N* over total population in each category is depicted.

COPD, chronic obstructive pulmonary disease.

Denotes *P* \< 0.05.
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We identified very few cases of other respiratory viral pathogens (Table [2](#jmv25006-tbl-0002){ref-type="table"}). *Human metapneumovirus* (*hMPV*) infections were more common in children (OR 5.9, 95%CI 1.8‐19.6, *P *= 0.006, Table [2](#jmv25006-tbl-0002){ref-type="table"}). Both *RSV* infections and human *metapneumovirus* infections were more frequent in children aged \<5 years old (*P* \< 0.001 for all associations). Rates of other viruses were comparable between children and adults.

Thirty‐four (5.6%) patients were hospitalized. The presence of any comorbidity was significantly associated with hospitalization (*P* = 0.001). In logistic regression models adjusting for all potential confounders higher age (beta: 0.03, OR 1.03, 95%CI 1.009‐1.04, *P *\< 0.01) and presence of a cardiovascular disease (beta: 0.99, OR 2.7, 95%CI 1.3‐5.5, *P *\< 0.01) were associated with a higher chance of hospitalization.

4. DISCUSSION {#jmv25006-sec-0005}
=============

A significant number of mixed viral respiratory infections was observed in the current study evaluating adults as well as children. Most mixed infections observed herein were *RSV*‐influenza co‐infections. Mixed viral infections were associated with younger age and increased rates of fever but were not associated with increased rates of hospitalization. We could not associate the presence of mixed infections with underlying comorbidities; however mixed viral infections appeared to be more frequent occurring than single infections in patients with comorbidities, patients with COPD and patients with cardiovascular disease. Nevertheless, it seems that our study did not have the power to elicit important differences in this regard.

In the current study, single as well as mixed viral infection was more common in children than adults. Multiple pediatric studies as well as a recent Greek study identified significant rates of mixed viral infections in the evaluated children population.[5](#jmv25006-bib-0005){ref-type="ref"}, [6](#jmv25006-bib-0006){ref-type="ref"}, [7](#jmv25006-bib-0007){ref-type="ref"}, [8](#jmv25006-bib-0008){ref-type="ref"}, [9](#jmv25006-bib-0009){ref-type="ref"}, [10](#jmv25006-bib-0010){ref-type="ref"}, [11](#jmv25006-bib-0011){ref-type="ref"}, [12](#jmv25006-bib-0012){ref-type="ref"}, [13](#jmv25006-bib-0013){ref-type="ref"}, [14](#jmv25006-bib-0014){ref-type="ref"} If higher percentages of pediatric population were included in our study mixed viral infection rates could have been higher.[21](#jmv25006-bib-0021){ref-type="ref"} Studies evaluating adult populations are scarce.[15](#jmv25006-bib-0015){ref-type="ref"}, [16](#jmv25006-bib-0016){ref-type="ref"}, [17](#jmv25006-bib-0017){ref-type="ref"}, [18](#jmv25006-bib-0018){ref-type="ref"} It appears that mixed viral infections may represent a significant percentage of adult upper respiratory tract infections albeit lower than pediatric ones.[17](#jmv25006-bib-0017){ref-type="ref"}, [18](#jmv25006-bib-0018){ref-type="ref"} The exact role of each virus in contributing to the pathogenesis of such infections is unclear.

We could not associate the presence of mixed viral infections or mixed *RSV* and influenza infections with severity of disease, or increased rates of hospitalization as claimed previously in most pediatric and adult studies.[5](#jmv25006-bib-0005){ref-type="ref"}, [15](#jmv25006-bib-0015){ref-type="ref"} Only one childhood study reported an inverse relationship between viral detection and need for oxygen therapy and hospitalization days.[14](#jmv25006-bib-0014){ref-type="ref"} Nevertheless, patients with mixed infections had higher rates of fever compared to the rest of the group. Other studies have not confirmed this association similarly to our findings.[9](#jmv25006-bib-0009){ref-type="ref"}, [10](#jmv25006-bib-0010){ref-type="ref"}, [16](#jmv25006-bib-0016){ref-type="ref"} Of interest, in our study single infections were associated with higher rates of hospitalization. This could be attributed to a systemic bias of: a) mixed infections being more common in younger children that usually run a milder clinical disease course; b) selection bias regarding the presentation to the Emergency Room of a tertiary care Hospital of more severe cases of respiratory infection that most often had single rather than mixed infection, and; c) the possibility that the additional virus detected was accidentally discovered when it was actually having a colonizing role. Furthermore, in the last two seasons of the study we had very few cases of *RSV* or mixed infections. Whether the coexistence of *RSV* and influenza meant: a) establishment of *RSV* prior to influenza infection or vice‐versa; b) the presence of one virus as a colonizer/pathogen that facilitated the establishment of the other or; c) both acted as co‐pathogens at the same time, is a matter, future studies should try to elucidate.

Regarding single virus infections the most prevalent respiratory viruses identified during the time of the study were influenza and *RSV*. Significant rates of *RSV* infection were noted during the winter season co‐circulating with the influenza virus even during the 2009‐10 pandemic season. Our prevalence data regarding influenza types concurred with the National Influenza surveillance scheme data that is flawed by the lack of data availability on co‐circulation of other viruses; this co‐circulation has been also confirmed in other efforts.[7](#jmv25006-bib-0007){ref-type="ref"}

Our study results concur with these of other studies showing rates of respiratory virus detection from 38.8% to as high as 52.1% in adults with upper respiratory infection or influenza like illness.[17](#jmv25006-bib-0017){ref-type="ref"}, [18](#jmv25006-bib-0018){ref-type="ref"} The higher percent of viral infections in children was not unexpected.[21](#jmv25006-bib-0021){ref-type="ref"}, [22](#jmv25006-bib-0022){ref-type="ref"} In particular, infections due to *RSV* and *hMPV* were more frequently observed in children compared to adults. Regarding the higher rates of *RSV* detection in children, *RSV* is well known to be a common pathogen in respiratory tract infections in children. Although not seen in our study, *RSV* can be a devastating pathogen in children that are very young or that have underlying illnesses[23](#jmv25006-bib-0023){ref-type="ref"}, [24](#jmv25006-bib-0024){ref-type="ref"}; more severe clinical outcomes and hospitalization have been described for children with *RSV* infection in our country.[25](#jmv25006-bib-0025){ref-type="ref"}

Human metapneumovirus was also more frequently seen in children in our study; as a virus it is known to affect younger children suffering from lower respiratory infections.[23](#jmv25006-bib-0023){ref-type="ref"}, [26](#jmv25006-bib-0026){ref-type="ref"}, [27](#jmv25006-bib-0027){ref-type="ref"} Increased awareness for this pathogen in younger ages is required. The new molecular techniques have facilitated identification of previously unappreciated pathogens in respiratory infections.

We diagnosed *RSV* infections in a significant percentage of our adult population. The role of *RSV* in producing adult respiratory infection is increasingly recognized.[28](#jmv25006-bib-0028){ref-type="ref"} *RSV* infections in adults are usually re‐infections and have a mild clinical picture.[28](#jmv25006-bib-0028){ref-type="ref"} In our study, *RSV* detection was not associated with hospitalization. *RSV* may be an important pathogen for specific adult subgroups like immunocompromised individuals or patients with acute exacerbation of chronic obstructive pulmonary disease[29](#jmv25006-bib-0029){ref-type="ref"}; however we did not see this association in our cohort. The role of *RSV* in producing a more severe disease especially in the adult population is a matter of debate.[30](#jmv25006-bib-0030){ref-type="ref"} In general, *RSV* appears to be associated with milder illness compared to influenza[31](#jmv25006-bib-0031){ref-type="ref"} however it has been associated with more severe disease in older subjects.[32](#jmv25006-bib-0032){ref-type="ref"}

Our study is limited by the fact that it examined population from a single center. Despite the risk of sampling bias, for example, not all patients examined, lack of a significant number of pediatric patients, the results of our samples closely correlate to national data obtained by a Hellenic Center for Disease Control and Prevention coordinated sentinel network that operates in more than 200 sites across the country and is much more representative of the general population. Data from this network depict that seasonal influenza starts around the end of each year (weeks 51‐52) and lasts up until around week 16‐18 of the next year each season (Table [3](#jmv25006-tbl-0003){ref-type="table"}, data available at <http://www.keelpno.gr>). Further, we could not adjust for any climatic effects in our viral detections. It has been reported that seasonality patterns for respiratory viruses circulation differ according to climatic conditions in different geographical areas,[33](#jmv25006-bib-0033){ref-type="ref"}, [34](#jmv25006-bib-0034){ref-type="ref"}, [35](#jmv25006-bib-0035){ref-type="ref"} although some studies have failed to show this.[36](#jmv25006-bib-0036){ref-type="ref"}, [37](#jmv25006-bib-0037){ref-type="ref"} Another limitation is that we could not exclude the possibility of *RSV* community outbreaks during the first 2 years of the study that could have forced more RSV infected patients to seek medical assistance. Variability of virus detection per collected samples per week of study during the 2010‐11 season (the highest RSV rates were noted then) suggest such a possibility for the last weeks of the study, when only RSV was detected. In addition, the limited data on other viruses besides the *influenza virus* and RSV is indicative of the dominance of these viruses during the winter season. Larger studies performed throughout the year, are necessary to clarify clinic‐epidemiological associations for other viruses; for example, *rhinoviruses* (usually circulating in other seasons) or *hMPV* and *bocavirus* (both were more common in children in this study). Finally, we could not exclude the possibility of viral presence in patients with low viral loads in the upper airways as a reason for not detecting a virus in most of our carefully selected patients. It is well known that lower respiratory secretions have higher yield in viral detection in respiratory infections. Similarly, nasopharyngeal samples or pooled nasopharygeal and oropharyngeal samples have been reported as more appropriate for analyzing respiratory infections.[38](#jmv25006-bib-0038){ref-type="ref"}, [39](#jmv25006-bib-0039){ref-type="ref"} It is well known that nasopharyngeal sampling is more sensitive in detecting respiratory viruses. The detection of viruses by molecular technique in an oropharyngeal sample collected through a standardized technique has facilitated vastly in the performance of our study in a busy Emergency Room. In a subsample of our study concerning almost one third of our patients, the method described herein correlated well with nasopharyngeal swabbing results (manuscript under preparation). Nevertheless, it is possible, that our analysis was biased towards cases with higher viral loads that gave positive results more frequently than cases with lower loads. In a similar manner, we could not account for bacterial coinfections in our subjects as most of the patients unless seriously ill were not examined with specific testing for the presence of bacterial co‐infection. It is has been recently reported that viral‐ bacterial coinfections are associated with a more complicated clinical course and adversely affect the prognosis of severe community---acquired pneumonia.[40](#jmv25006-bib-0040){ref-type="ref"} Nevertheless as shown in previous studies most of the acute respiratory infections in the general population are of viral origin.[41](#jmv25006-bib-0041){ref-type="ref"}

In conclusion, we describe for the first time in Greece, a large population based epidemiology study concerning the molecular detection of mixed viral respiratory infections in people presenting to a major tertiary care center. Newer molecular techniques assisted in diagnosing mixed viral infections in a significant fraction of our population. Although data from our study concur with data from several published pediatric studies, we believe that our study\'s main strength is that it is one of the very few epidemiological studies examining mixed respiratory viruses in adults. Further, as an epidemiological study it does not attempt to explain a hypothesis; rather it assists in generating hypotheses regarding the role of mixed viral infections in the adult population and points out the lack of data in this significant research area. Further work is necessary to elucidate the pathogenic role of mixed infections due to respiratory viruses and their local and systemic effects.

CONFLICTS OF INTEREST {#jmv25006-sec-0007}
=====================

No financial or other conflict of interest exists, that might be construed to influence the contents of the current manuscript, including the results or interpretation of publication.

This research received no specific grant from any funding agency, commercial or not‐for‐profit sectors.
